Reply to S. Zeng et al
- PMID: 35704836
- DOI: 10.1200/JCO.22.01031
Reply to S. Zeng et al
Conflict of interest statement
Comment on
-
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin as the Gold Standard Neoadjuvant Chemotherapy Regimen for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer Remains Controversial.J Clin Oncol. 2022 Sep 10;40(26):3093-3094. doi: 10.1200/JCO.22.00669. Epub 2022 Jun 15. J Clin Oncol. 2022. PMID: 35704788 No abstract available.
Publication types
LinkOut - more resources
Full Text Sources
